PDA's New Technical Report for Biotech Cleaning Validation - The authors encourage biotech manufacturers to consult PDA Technical Report No. 49 for a detailed perspective on current practices and issu

ADVERTISEMENT

PDA's New Technical Report for Biotech Cleaning Validation
The authors encourage biotech manufacturers to consult PDA Technical Report No. 49 for a detailed perspective on current practices and issues in biotech cleaning validation.


BioPharm International
Volume 24, Issue 3, pp. 26-34

RISK MANAGEMENT AND ASSESSMENT

Quality risk management (QRM) involves elements of risk assessment, risk control, and periodic review to ensure continuous and effective control (6). It is important to achieve a shared understanding of the application of risk management among diverse stakeholders. Successful implementation of QRM requires support of the whole team, including operations, technical services, engineering, quality control, quality assurance, and regulatory personnel. This support is essential to identifying and addressing conditions that affect CPPs and CQAs for the cleaning or manufacturing process.

CONCLUSION

This article has reviewed the key issues in biotech cleaning validation. The authors encourage all biotech manufacturers to consult PDA Technical Report No. 49 for a detailed perspective on current practices and issues in biotech cleaning validation.

Anurag S. Rathore* is a biotechnology chemistry, manufacturing, and controls consultant and a faculty member at the Indian Institute of Delhi, India, +91 9650770650,
. Rathore is also a member of BioPharm International's editorial advisory board. Destin A. LeBlanc is the principal consultant at Cleaning Validation Technologies.

*To whom all correspondence should be addressed.

REFERENCES

1. PDA, Technical Report No. 49: Points to Consider for Biotechnology Cleaning Validation (PDA, Bethesda, MD, July 2010).

2. PDA, Technical Report No. 29: Points to Consider for Cleaning Validation (PDA, Bethesda, MD, Nov. 1998).

3. PDA, Technical Monograph, Cleaning and Cleaning Validation: A Biotechnology Perspective (PDA, Bethesda, MD, Dec. 1995).

4. ICH, Q2 (R1) Validation of Analytical Procedures: Text and Methodology, Step 4 version (2005).

5. ICH, Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Step 4 version (2000).

6. ICH, Q9 Quality Risk Management, Step 4 version (2005).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here